<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03001804</url>
  </required_header>
  <id_info>
    <org_study_id>CC-5013-MM-037</org_study_id>
    <nct_id>NCT03001804</nct_id>
  </id_info>
  <brief_title>Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients</brief_title>
  <official_title>Use of Lenalidomide (Revlimid®) in Combination With Dexamethasone in Untreated Non-transplantable Multiple Myeloma in Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this non-interventional study is to collect primarily the percentage of patients&#xD;
      who receive the full dose of dexamethasone (20 or 40 mg orally once daily on days 1, 8, 15&#xD;
      and 22 of the repetitive 28-day cycles, 20 mg in &gt;75 year old patients) in the registered&#xD;
      indication under practice conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple myeloma is still a persistent and life-threatening blood cancer that is&#xD;
      characterised by tumour proliferation and suppression of the immune system. It is a rare but&#xD;
      incurable disease. On average, multiple myeloma is diagnosed in people 65-74 years of age,&#xD;
      and the majority of newly diagnosed patients may not be eligible for more aggressive&#xD;
      treatment options such as high-dose chemotherapy with stem cell transplant. In February 2015&#xD;
      REVLIMID® (lenalidomide) was approved in combination with dexamethasone for the treatment of&#xD;
      adult patients with previously untreated multiple myeloma who are not eligible for&#xD;
      transplant. Furthermore, in May 2019 REVLIMID® was approved in combination with bortezomib&#xD;
      and dexamethasone for the treatment of adult patients with previously untreated multiple&#xD;
      myeloma who are not eligible for transplant.&#xD;
&#xD;
      Looking in more detail at the combination of lenalidomide and dexamethasone, the role and&#xD;
      especially the most adequate and effective dosage of dexamethasone in long term use with&#xD;
      lenalidomide is not clearly defined or well characterised It is therefore of great relevance&#xD;
      to gain insights into the clinical practice and the routine of dexamethasone management and&#xD;
      dosing in long term use with Revlimid.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients receiving dexamethasone after 6 months of treatment</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Number of patients receiving 20mg or 40mg dexamethasone on day 1, 8, 15, 22 of a 28 day cycle after 6 months of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with Deep Venous Thrombosis (VTE) prophylaxis</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Number of patients that receive VTE prophylaxis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Over all response rate (ORR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Number of patients that achieve a response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Number of patients with an adverse events</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <description>Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr &lt; 50mg/min) capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (&gt;75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <description>Initial treatment (up to 8 cycles): Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr &lt; 50mg/min) capsule by mouth (PO) on day 1 through 14 of a 21 day cycle, Bortezomib 1.3mg/m2 s.c. on day 1, 4, 8, and 11 of a 21 day cycle, and Dexamethasone 20mg PO on days 1,2,4,5,8,9,11,12 of a 21 day cycle; Successive Treatment: Lenalidomide 25mg or 10mg (reduced renal function 30 ≤ ClCr &lt; 50mg/min) capsules by mouth (PO) on days 1 through 21 of a 28 day cycle and Dexamethasone 40mg PO (≤75 years) or 20mg (&gt;75years) on Days 1, 8, 15, 22 of a 28 day cycle until progression or unacceptable toxicity</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients scheduled for therapy of untreated multiple myeloma, where stem cell&#xD;
        transplantation cannot be performed&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed Informed Consent&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Newly diagnosed Multiple Myeloma&#xD;
&#xD;
          -  Not suitable for stem cell transplantation&#xD;
&#xD;
          -  Appropriate methods of contraception according to the Risk Minimization Program (RMP)&#xD;
&#xD;
          -  Adequate thrombosis prophylaxis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and lactating females&#xD;
&#xD;
          -  No other formal exclusion criteria according to most recent European Summary of&#xD;
             Product Characteristics (SmPC)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guenter Voraberger</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Landeskrankenhaus Kirchdorf</name>
      <address>
        <city>Kirchdorf</city>
        <zip>4560</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikum Klagenfurt am Wörthersee</name>
      <address>
        <city>Klagenfurt</city>
        <zip>9020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kepleruniversitätsklinikum GmbH, Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH Elisabethinen</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern Ried Innere Medizin 1</name>
      <address>
        <city>Ried</city>
        <zip>4910</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Landeskrankenhaus Steyr - Innere Medizin</name>
      <address>
        <city>Steyr</city>
        <zip>4400</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinische Abteilung für Hämatologie und Hämostaseologie</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Josef Krankenhaus</name>
      <address>
        <city>Vienna</city>
        <zip>1130</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital, 1. Med.Abteilung, Zentrum für Onkologie</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Salzkammergut-Klinikum Vöcklabruck Abteilung Innere Medizin</name>
      <address>
        <city>Vöcklabruck</city>
        <zip>4840</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AKH, Innere Medizin I, Klinische Abteilung für Hämatologie und Hämostaseologie</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LKH Wiener Neustadt, Innere Medizin</name>
      <address>
        <city>Wr. Neustadt</city>
        <zip>2700</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>December 22, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2016</study_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Revlimid</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>Non-transplantable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

